Font Size: 

Background: Vigabatrin is anantiepileptic drug that it,s visual field defects are usuallyasymptomatic and only detectable by perimetry.Electroretinogram responseamplitude to full-field 30-Hz flicker shine has been offered to be morespecific in predicting visual field defects. This study was designed to determine the efficacy of Vigabatrinin Iranian children with intractable epilepsy and its visual adverse effects. Method:Children with epilepsy taking vigabatrin referred toChildren’s Medical Center and Mofid Children Hospital between November 2012 andOctober 2013 were enrolled in the study. Seizure periodicity and severity wereevaluated within 3–4 weeks after Vigabatrin initiation.  Full-field electroretinography wasconducted for all patients every 3 months. Result:This study included 67 patients.The average age ofpatients was 3.1+2.6 years. The age of seizure onset was 1 day to 5 years, andthe mean age at seizure onset was 8.57 + 12.8 months. Daily seizures werereduced by ≤56% and 54.5% after three and six months of Vigabatrin therapy. Theresponder rate, which means a reduction of >50% in seizure severity andduration, was 67.2% and 56.7% at three and six months of Vigabatrin therapy,respectively.  Electroretinographic surveys showed normal range parametersdespite 3 months of vigabatrin treatment, and just 3 (4.47%) children had beenvisually impaired at the end of 6-month treatment.Conclusion:In conclusion, this study confirms the short-termefficacy and safety of Vigabatrin in children with refractory epilepsies.Wesuggest that vigabatrin is secure for short-term pediatric antiepileptictreatment, with few cases of visual impairments and that are often reversible.Keywords: Intractable epilepsy, Antiepilepticdrugs, Vigabatrin, Add-on therapy, Side effects.Keywords: Intractableepilepsy, Antiepileptic drugs, Vigabatrin, Add-on therapy, Side effects.

Intractableepilepsy, Antiepileptic drugs, Vigabatrin, Add-on therapy, Side effects.